Compare ELVN & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELVN | EWTX |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.3B |
| IPO Year | 2020 | 2021 |
| Metric | ELVN | EWTX |
|---|---|---|
| Price | $46.48 | $39.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | ★ $74.33 | $56.17 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.17 | N/A |
| EPS | N/A | ★ 8.86 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.65 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.79 | $19.76 |
| 52 Week High | $62.32 | $48.78 |
| Indicator | ELVN | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 44.25 |
| Support Level | $44.18 | $37.22 |
| Resistance Level | $46.96 | $41.60 |
| Average True Range (ATR) | 2.47 | 3.20 |
| MACD | -0.17 | -0.37 |
| Stochastic Oscillator | 25.69 | 26.45 |
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.